Monday, February 28, 2011 10:57:12 AM
In a note to clients, Deutsche Bank writes, "We are updating our model based on trends for currently marketed products and the discontinuation of LipoSonix and Plexion. We are modestly lowering our EPS ests from $2.53 to $2.51 in 2011, $2.85 to $2.80 in 2012, and $3.19 to $3.14 in 2013. Our new 12-month PT is $36, based on 13x our new 2012 EPS est. Potential risks to our PT being achieved principally relate to the aesthetic franchises and Rx trends for Solodyn and Ziana."
Read more: http://www.benzinga.com/analyst-ratings/analyst-color/11/02/889975/update-deutsche-bank-raises-pt-on-medicis-pharmaceutical-#ixzz1FGmXw0Qd
Recent MRX News
- Marex Group plc to Report FY 2023 Results and Q1 2024 Update on May 16, 2024 • GlobeNewswire Inc. • 05/13/2024 09:40:40 PM
- Marex Group plc Announces Pricing of Initial Public Offering • GlobeNewswire Inc. • 04/25/2024 01:33:37 AM
- Marex Group plc Announces Launch of Initial Public Offering • GlobeNewswire Inc. • 04/15/2024 01:19:28 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM